Key result
Addition of hydralazine plus nitrates to standard therapy in patients with chronic heart failure did not significantly reduce 60-day mortality compared to standard therapy alone (10% vs 17.5%, p=0.549).
Why the study?
Does the addition of hydralazine and isosorbide dinitrate to standard therapy reduce mortality and recurrent hospitalizations in patients with chronic heart failure (NYHA III-IV)?
Cohort (n=80)
Open-label
No
Does the addition of hydralazine and isosorbide dinitrate to standard therapy reduce mortality and recurrent hospitalizations in patients with chronic heart failure (NYHA III-IV)?
No mortality benefit seen with hydralazine-nitrates addition in chronic HF; leaves open readmission effects for randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
D et al. (2018) conducted a cohort in Chronic Heart Failure (n=80). Hydralazine-isosorbide dinitrate vs. Standard anti-failure therapy was evaluated on 60-day mortality (p=0.549). Addition of hydralazine plus nitrates to standard therapy in patients with chronic heart failure did not significantly reduce 60-day mortality compared to standard therapy alone (10% vs 17.5%, p=0.549).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: